US/UK/Canada

Share

Links

Quotes

This order is of strategic importance for Attana, since we are now involved at an early stage in designing R&D projects for a major drug development project. The order shows a market acceptance for our technology and capability to characterize interactions with cells, tissues, viruses etc it also provides a value of our application knowledge and the advises we can provide.
International Sales Manager Thomas Ljungberg
Pick a time period -
Tags ( Active)

New paper using Attana Technology: A broadly potent antibody targeting the different Covid-19 mutations

The team of Prof Ali Salanti at University of Copenhagen has in a new publication  identified a human monoclonal antibody from a health worker that has strong neutralizing capacity against the different Covid-19 mutations. The results using Attana technology once again confirms the importance of fast and persistent interaction between the antibody and the virus to obtain good neutralizing capacity and thereby good protection.The relatively fast mutations of SARS-COV-2 virus is an issue both for vaccination and therapeutics. There is today

New paper using Attana technology for development of therapeutic antibodies against cancer

We are very happy that Attana technology has more or less from the start been involved in taking a malaria parasite protein towards a generic cancer treatment!   The latest work, published in Nature Communications  describes that translation into clinical trials turned out to be complicate e.g. by complex manufacturing and expensive scale-up processes of the malaria protein. Converting it into antibodies turned out to be the trick.   Antibody manufacturing is significantly less complicated than protein manufacturing. Attana

Attana technology applied in malaria vaccine development to determine the neutralizing effect of sera

In a new publication in “Vaccines ” from Department of Immunology and Microbiology, Centre for translational Medicine & Parasitology at Copenhagen University, Attana technology has been applied to determine the interaction kinetics between antibodies from vaccinated mice and the pathogen antigen used for the vaccines. This provides valuable information for creating a vaccine with optimal neutralizing effect and hence a high level of protection for the individuals.In the study two types of vaccines have been compared.  A traditional pathogen peptide

BioInvent evaluating Attana Technology

BioInvent and Attana has signed a three-month evaluation agreement. BioInvent is a clinical-stage company that discovers and develops antibodies for cancer therapy. Based on extensive knowledge in immunology, cancer biology and antibody biology, BioInvent generates innovative immuno-oncology drug candidates.Attana will in May install Attana Cell™ 250 instrument and train users at BioInvents labs in Lund. During the evaluation period cell- and sera-based assays will be performed to study interactions between antibodies and target cells.

New paper using Attana Technology to study structures on surface in Ion Liquids demonstrating the effect of surface charges on interaction properties.

In the paper in "Journal of Colloid And Interface Science ", the Attana quartz crystal microbalance (QCM) is applied to study the electrical response of two ionic liquids. Controlled by an applied electric field, the structure and interaction of ionic liquids on the surface, can be monitored and optimized. This is of high importance for the development of e.g. environment friendly lubricants. This is the third paper by the team of Prof Rutland that demonstrates how Attana technology can be applied to monitor interaction

New article using Attana's technology from National University of Singapore: Immunity differences in vaccinated individuals according to age, gender, lifestyle and other diseases

The article  presented quantification of serological immunity against SARS-CoV-2 variants. Differences in immunity are seen against the different variants and depending on age, sex, ethnicity and lifestyle, but e.g. high blood pressure or BMI did not show significant differences in the serological immunity of individuals vaccinated against the Wuhan variant. The study also showed poorer immunity to Omicron than to Wuhan, but after the third vaccine dose, an increased cross-reactivity between the different covid variants was shown.To

Biosensors to characterize immune response to bacterial diseases

Within the research project “Advanced Materials for Personalized Medicine and Diagnostics  (AMPMeD)” at the Linnaeus University, the sub-projects, “Enhanced bacterial infection diagnosis” lead by Dr. Sofia Somajo is now initiating test of Borrelia infected individuals. Sera and dry blood samples will be tested according to Attanas immunity profiles concept.The AmPMeD project started previously this year and includes the entire chain from sampling, via analysis to reporting. The

Attana and Linnaeus University have published the first part of the science behind immunity profiles

In the International Journal of Molecular Science , Attana and Linnaeus University have published the validation of Attana's QCM technology for IgG detection and determination for in-vitro diagnostics. The technique has been validated against electrochemiluminescence immunoassay (ECLIA) and chemiluminescence immunoassay (CLIA). The results in this publication are an important part in the development of Attana's immunity profiles.In the publication Quartz Crystal Microbalance Platform for SARS-CoV-2 Immuno-Diagnostics, Attana's QCM technology has

New publication from National University of Singapore using Attana Technology to study Immune Response from Tuberculosis Exposed Healthy Individuals

In a new paper in npj Vaccines, 8, Article number: 127 (2023) , the team at NUS, in collaboration with several research groups in USA, UK and, China has studied the immune response from healthy individuals that have been exposed to Tuberculosis (TB). TB is an airborne disease caused by Mycobacterium tuberculosis. Identifying the critical components in the antibody repertoires from immune, chronically exposed and, healthy individuals can be used for understanding how natural protection occurs. These findings have implications for future

The Swedish Knowledge-Foundation has granted SEK 12 million to a project concerning individual immunity profiles for diagnostics and medical development based on Attana's QCM technology.

The Swedish Knowledge-Foundation has granted SEK 12 million to the project "Advanced materials for individualized medicine and diagnostics ". The project is coordinated by Prof. Ian Nicholls at Linnaeus University  in collaboration with Attana AB, AroCell AB, Capitainer AB, Luma Metall AB and Region Kalmar.The aim of the project is to provide precise information about the medical conditions of

Attana enters the second year of a five-year service and support contract with a leading health institute in the US

We are now entering the second year of increased presence at the US. We are now stepping into the second year of a long-term agreement of full-service and support with one of our future reference sites. The coming 12 month we look forward to new users and upcoming exciting experiments enabled by the Attana platform. Read more here about the startup of the contract: 

Attana and 19 Plus AB (Testmottagningen.se by Zample) sign collaboration agreement of marketing and sales of Attana individual immunity profiles

Attana can today announce that the company has signed a collaboration agreement with 19 Plus AB for the marketing and sales of Attana individual immunity profiles for Covid 19.Testmottagingen.se  by Zample (a brand name owned by 19 Plus AB) started operations in connection with the pandemic outbreak to meet the demand for covid test for travelling. The operations have thereafter expanded to include different health tests which will soon include individual immunity profiles by Attana with respect to wuhan and omicron mutations. The ambition is to by

New publication where Attana technology has been applied for lead candidate selection of a new antibody-based anti-viral treatment of Hepatitis B infection

The team of prof. P. A. MacAry at the Department of Medicine, National University of Singapore has in NPJ Vaccines (npj Vaccines (2022)7:121 ) published a new paper revealing an important understanding of human immunity to Hepatitis B Virus (HBV). Their findings can potentially represent a new antibody-based anti-viral candidate for therapy for HBV infection.Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease. WHO estimates that almost 300 million people were living with

Attana’s QCM technology contributes to enhancement of cancer diagnosis through lectin-cancer tissues interaction

Cancer is one of the major health threats all over the world leading to high death mortality rates with approximately 10 million deaths in 2020 (WHO). Early diagnosis of malignant diseases including cancer is considered one of the most effective tools to decrease the cancer burden and reduce the treatment costs. Finding novel selective diagnostic agents that could target and differentially distinguish the cancer cells would improve the cancer diagnosis and treatment.  Lectins are carbohydrate binding proteins commonly found in diverse sources in nature such as plants, bacteria, animals,

Attana’s presentation from Småbolagsdagarna is now available on YouTube

On June 14, Attana attended Aktiespararna’s Småbolagsdagarna where CEO, Teodor Aastrup, gave a 20-minute-long presentation followed by a 10-minute-long Q&A.The presentation was held in Swedish and primarily focused on Attana’s history and milestones, followed by Attana’s ongoing work within both its business areas – Life Science and Diagnostics. The presentation concluded with Attana long-term, 2030 plan. The presentation can be accessed by following this link: Attana – Småbolagsdagarna 2022 

New publication using Attana Technology for interaction studies of antibodies with extracellular vesicle

The characterization of extracellular vesicles interactions is important to gain understanding of several diseases. In this paper the universities in Helsinki and Karlstad have collaborated and used state of the art technology to analyse extracellular vesicles obtained from human blood plasma. The extracellular vesicles interaction with antibodies and transmembrane proteins were detailed characterized and hence opens up for increased understanding extracellular vesicles roles in several diseases.Extracellular vesicles (EVs) are nanosized lipid particles (50–3000nm) released from cells that

Attana's presentation from Erik Penser Bank's Bolagsdag is now available on Attana's website

On March 10, 2022, CEO Teodor Aastrup gave a presentation in connection with Erik Penser Bank's Bolagsdag.The presentation gave an introduction to Attana's two business areas, Life Science and Diagnostics, as well as an update on Attana's track record in drug development and Attana's patent portfolio. The presentation can be viewed on Attana's website by following this link: Attana – Erik Penser Bank Bolagsdag 2022 

New publication using Attana Technology for developing synthetic antibodies

The detection of proteins and peptides is necessary in many clinical diagnostics applications and has been of high importance during the pandemic. Detection using antibodies is well established due to their high specificities and selectivity. However, they have limited chemical- and physical stabilities concerning shelf lives and transport. This paper describes the development of synthetic antibodies with high stability, and the comparable specificity and selectivity for commercially available antibodies.The team of Prof. Nicholls at the Linnaeus University describes how they have developed

Attana receives a Cell™ 250 instrument order from a European Life Science company

Attana has received an order for a Cell™ 250 instrument from a European Life Science company. This is the client’s second Attana instrument and is the result of a successful use and the client’s growth plans.The Cell™ 250 instrument will be installed during Q1 2022 and will positively affect Attana earnings in Q1 2022 and cash flow for the remainder of the year. “We strive to be close partner with our clients. This order is a result of this and our ability to grow together with our clients. We see good potential in increased further collaboration” comments Teodor Aastrup, CEO Attana.

Attana and AroCell initiates discussion for collaboration

Attana can today announce that the company has initiated a discussion about a new collaboration with the in vitro diagnostics company AroCell AB (Publ).AroCell AB is a Swedish company that develops and markets blood and urine sample tests and specializes in oncology and bacteriology. The company has a broad product portfolio that is used in healthcare and is established in various markets. The collaboration aims to exchange valuable knowledge in quality and product development, while AroCell's biomarkers can eventually be used on Attana's instruments. Teodor Aastrup, CEO Attana comments:

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe